NextCure Inc. is merging with privately held Avere Therapeutics in an all-stock transaction, effectively taking Avere public and securing $320 million in financing. This deal transforms NextCure into Avere Therapeutics, focusing on advancing AVR-001, an oral IL-23 therapy for inflammatory diseases, and is a significant strategic shift for NextCure.
NextCure (NXTC) is undergoing a reverse merger with Avere Therapeutics, effectively becoming Avere and trading under a new ticker (AVRX). This is a major strategic pivot for NextCure, as it shifts its focus entirely to Avere's lead oral IL-23 therapy, AVR-001, for psoriasis and ulcerative colitis. The accompanying $320 million financing, led by Fairmount and Hansoh Pharmaceutical Group, is crucial as it funds operations through key clinical trial readouts, including a global Phase 2b psoriasis trial and the start of a Phase 3 study. For NXTC shareholders, this represents a significant change, with pre-merger shareholders owning only 1.21% of the combined company, but also receiving a contingent value right for NextCure's legacy assets. The short-term impact on NXTC has been highly positive, as evidenced by the stock's surge, reflecting investor optimism about the new direction and funding. Long-term success hinges on the clinical trial outcomes of AVR-001.